ibrutinib - Articles and news items


Janssen’s IMBRUVICA® receives recommendation to broaden treatment application for CLL patients

Industry news / 3 May 2016 / Mandy Parrett, Editorial Assistant

Janssen-Cilag International NV have reported that their therapy IMBRUVICA® (ibrutinib) has received a ‘Positive Opinion’ from the CHMP recommending that its use be extended for CLL patients.


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...